Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
stomach cancer
Pharma
FDA limits Keytruda, Opdivo uses in stomach cancer
The two PD-1 inhibitors' FDA labels in gastric, gastroesophageal junction and esophageal cancers have been reduced to PD-L1-positive tumors only.
Angus Liu
Jun 9, 2025 10:50am
ASCO: AZ looks to bring immunotherapy to early stomach cancer
Jun 1, 2025 8:00am
AstraZeneca says Imfinzi keeps stomach cancer from coming back
Mar 7, 2025 9:48am
AZ, Daiichi's Enhertu delivers survival win in stomach cancer
Mar 3, 2025 3:43pm
Merck, Eisai combo misses survival goal in GI cancer trial
Jan 24, 2025 10:26am
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
